Ab­b­Vie dou­bles down on cys­tic fi­bro­sis R&D, adding a new drug to the pipeline as Ver­tex seals its dom­i­na­tion of the field with Trikaf­ta OK

Ab­b­Vie turned some heads last fall when the phar­ma gi­ant an­nounced plans to scoop up a port­fo­lio of cys­tic fi­bro­sis drugs from their part­ners at Gala­pa­gos in a $245 mil­lion deal — af­ter the lat­est da­ta came out look­ing par­tic­u­lar­ly weak com­pared to what Ver­tex was re­port­ing. Still ig­nor­ing the doubters, Ab­b­Vie is dou­bling down, bring­ing in a pre­clin­i­cal CFTR po­ten­tia­tor com­pound from the Cys­tic Fi­bro­sis Foun­da­tion to sharp­en its com­bo ap­proach.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER